Table 2.
Treatment-related adverse events reported in 2 or more patients
| AE | Grade 1 n (%) |
Grade 2 n (%) |
Grade 3 n (%) |
Grade 4 n (%) |
Total n (%) |
|---|---|---|---|---|---|
| Any AE | 15 (57.7) | 4 (15.4) | 3 (11.5) | 0 | 22 (84.6) |
| Fatigue | 9 (34.6) | 1 (3.8) | 0 | 0 | 10 (38.5) |
| Photophobia | 5 (19.2) | 1 (3.8) | 1 (3.8) | 0 | 7 (26.9) |
| Decreased appetite | 5 (19.2) | 1 (3.8) | 0 | 0 | 6 (23.1) |
| Dry eye | 4 (15.4) | 2 (7.7) | 0 | 0 | 6 (23.1) |
| Nausea | 4 (15.4) | 2 (7.7) | 0 | 0 | 6 (23.1) |
| Thrombocytopenia | 2 (7.7) | 3 (11.5) | 1 (3.8) | 0 | 6 (23.1) |
| Vomiting | 3 (11.5) | 2 (7.7) | 0 | 0 | 5 (19.2) |
| Eye pain | 3 (11.5) | 0 | 1 (3.8) | 0 | 4 (15.4) |
| Increased AST | 0 | 2 (7.7) | 1 (3.8) | 0 | 3 (11.5) |
| Headache | 3 (11.5) | 0 | 0 | 0 | 3 (11.5) |
| Blurred vision | 1 (3.8) | 2 (7.7) | 0 | 0 | 3 (11.5) |
| Increased ALT | 2 (7.7) | 0 | 0 | 0 | 2 (7.7) |
| Anemia | 1 (3.8) | 1 (3.8) | 0 | 0 | 2 (7.7) |
| Conjunctivitis | 0 | 2 (7.7) | 0 | 0 | 2 (7.7) |
| Dysgeusia | 1 (3.8) | 1 (3.8) | 0 | 0 | 2 (7.7) |
| Increased lacrimation | 2 (7.7) | 0 | 0 | 0 | 2 (7.7) |
| Peripheral sensory neuropathy | 2 (7.7) | 0 | 0 | 0 | 2 (7.7) |
| Vitreous floaters | 2 (7.7) | 0 | 0 | 0 | 2 (7.7) |
AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase